# Ollin Biosciences funding rounds and investors

As of 14 Oct 2026, Ollin Biosciences has raised $430M across 2 verified rounds on record; latest: $330 million Series B led by TCGX and Arch Venture Partners, announced 24 Jun 2026.

Ollin sells innovative therapies targeting serious eye diseases for patients.

Website: https://ollin.bio  
Page: https://fireround.dev/companies/ollin.bio

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-06-24 | Series B | $330 million | TCGX, Arch Venture Partners | a16z Bio + Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, T. Rowe Price, Mubadala Capital, Monograph | [ollin.bio](https://ollin.bio/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026) |
| 2025-09-17 | Funding round | $100 million | Arch Venture Partners, Mubadala Capital, Monograph | none named | [biopharmadive.com](https://www.biopharmadive.com/news/ollin-biosciences-ophthalmology-startup-vabysmo-tepezza/760182) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.